Comparative Pharmacology
Head-to-head clinical analysis: M ZOLE 7 DUAL PACK versus VFEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M ZOLE 7 DUAL PACK versus VFEND.
M-ZOLE 7 DUAL PACK vs VFEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
M-ZOLE 7 DUAL PACK contains miconazole, an imidazole antifungal that inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity, and increasing permeability, leading to cell death.
Inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Adults: One vaginal tablet (containing 500 mg metronidazole and 150 mg miconazole nitrate) inserted vaginally once daily at bedtime for 7 days.
IV: Loading dose of 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. Oral: Weight ≥40 kg: Loading dose of 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours; weight <40 kg: Loading dose of 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours.
None Documented
None Documented
Terminal half-life approximately 48–72 hours. Prolonged in renal impairment (up to 72–120 hours in ESRD), requiring dose adjustment.
Terminal half-life is approximately 24 hours (range 12–30 h) in adults. Prolonged in hepatic impairment (Child-Pugh A: 48 h; B: 72 h).
Primarily renal (80% unchanged drug, 20% as metabolites); biliary/fecal excretion is minimal (<5%).
Primarily hepatic metabolism; <2% excreted unchanged in urine. Fecal excretion accounts for ~80% of metabolites. Renal excretion of unchanged drug is negligible.
Category C
Category C
Antifungal
Antifungal